AU2020223284A1 - Compositions and methods for treatment of depression and other disorders - Google Patents

Compositions and methods for treatment of depression and other disorders Download PDF

Info

Publication number
AU2020223284A1
AU2020223284A1 AU2020223284A AU2020223284A AU2020223284A1 AU 2020223284 A1 AU2020223284 A1 AU 2020223284A1 AU 2020223284 A AU2020223284 A AU 2020223284A AU 2020223284 A AU2020223284 A AU 2020223284A AU 2020223284 A1 AU2020223284 A1 AU 2020223284A1
Authority
AU
Australia
Prior art keywords
nri
maoi
aspects
hours
phenelzine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020223284A
Other languages
English (en)
Inventor
Magid Abraham
Ken GILLMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeuraWell Therapeutics Inc
Original Assignee
NeuraWell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NeuraWell Therapeutics Inc filed Critical NeuraWell Therapeutics Inc
Publication of AU2020223284A1 publication Critical patent/AU2020223284A1/en
Priority to AU2023226657A priority Critical patent/AU2023226657A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AU2020223284A 2019-02-17 2020-02-18 Compositions and methods for treatment of depression and other disorders Abandoned AU2020223284A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023226657A AU2023226657A1 (en) 2019-02-17 2023-09-05 Compositions and methods for treatment of depression and other disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962806831P 2019-02-17 2019-02-17
US62/806,831 2019-02-17
PCT/US2020/018567 WO2020168337A1 (en) 2019-02-17 2020-02-18 Compositions and methods for treatment of depression and other disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023226657A Division AU2023226657A1 (en) 2019-02-17 2023-09-05 Compositions and methods for treatment of depression and other disorders

Publications (1)

Publication Number Publication Date
AU2020223284A1 true AU2020223284A1 (en) 2021-09-16

Family

ID=72045151

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020223284A Abandoned AU2020223284A1 (en) 2019-02-17 2020-02-18 Compositions and methods for treatment of depression and other disorders
AU2023226657A Abandoned AU2023226657A1 (en) 2019-02-17 2023-09-05 Compositions and methods for treatment of depression and other disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023226657A Abandoned AU2023226657A1 (en) 2019-02-17 2023-09-05 Compositions and methods for treatment of depression and other disorders

Country Status (7)

Country Link
US (1) US12465611B2 (cg-RX-API-DMAC10.html)
EP (1) EP3923919A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022521208A (cg-RX-API-DMAC10.html)
CN (1) CN113631157A (cg-RX-API-DMAC10.html)
AU (2) AU2020223284A1 (cg-RX-API-DMAC10.html)
CA (1) CA3130580A1 (cg-RX-API-DMAC10.html)
WO (1) WO2020168337A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4727545A2 (en) * 2023-06-16 2026-04-22 Neurawell Therapeutics Combination treatments for depression and other disorders

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999382A (en) 1988-10-26 1991-03-12 Massachusetts Institute Of Technology Compositions for treating tobacco withdrawal symptoms and methods for their use
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20040102440A1 (en) 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
EP1715843A1 (en) * 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
EP1737473A4 (en) 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
KR20080013853A (ko) 2005-02-23 2008-02-13 사이케노믹스, 인코퍼레이티드 복수매개물질 도파민 수송체 저해물질 및 이와 관련된 용도
CA2598838A1 (en) 2005-02-23 2006-08-31 Prexa Pharmaceuticals, Inc. Multimediator 5-ht6 receptor antagonists, and uses related thereto
KR20080003849A (ko) 2005-03-31 2008-01-08 아밀린 파마슈티칼스, 인크. 비만 및 섭식 장애의 조절, 예방 및 치료를 위한 조성물 및방법
JP2008538576A (ja) 2005-04-22 2008-10-30 ワイス クロマンおよびクロメン誘導体およびその使用
CN101198322A (zh) 2005-04-22 2008-06-11 惠氏公司 用于治疗或预防抑郁症的新治疗组合
JP2009531435A (ja) 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
AU2008226541B2 (en) * 2007-03-09 2013-05-09 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
ES2431570T3 (es) * 2007-05-07 2013-11-27 Chelsea Therapeutics, Inc. Droxidopa y composición farmacéutica de la misma para el tratamiento de los trastornos por déficit de atención
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US20110262442A1 (en) 2009-11-06 2011-10-27 Adenios, Inc. Compositions for treating cns disorders
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
WO2011119227A2 (en) 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
US10463633B2 (en) 2010-04-23 2019-11-05 Kempharm, Inc. Therapeutic formulation for reduced drug side effects
US20130324609A1 (en) 2010-10-08 2013-12-05 University Of Utah Research Foundation Depression disorder therapeutics with creatine analogs
US20130217673A1 (en) 2012-02-22 2013-08-22 Warsaw Orthopedic, Inc Mixed monoamine reuptake inhibitor in a biodegradable polymer carrier
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
CA2899455C (en) 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
KR20230116948A (ko) 2016-03-10 2023-08-04 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
US10624939B2 (en) 2017-05-23 2020-04-21 Luke Klele Natural product compositions for treating or managing symptoms of ADD, ADHD, anxiety, and depression
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
CN111233737B (zh) 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途

Also Published As

Publication number Publication date
WO2020168337A4 (en) 2020-10-08
EP3923919A1 (en) 2021-12-22
AU2023226657A1 (en) 2023-09-21
US12465611B2 (en) 2025-11-11
US20220117975A1 (en) 2022-04-21
WO2020168337A1 (en) 2020-08-20
JP2022521208A (ja) 2022-04-06
CA3130580A1 (en) 2020-08-20
EP3923919A4 (en) 2022-12-07
CN113631157A (zh) 2021-11-09

Similar Documents

Publication Publication Date Title
Cheer et al. Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness
Kessler et al. Mood disorders: Bipolar and major depressive disorders
JP7852200B2 (ja) ウィルソン病を治療するためのビスコリンテトラチオモリブデート
HK1252658A1 (zh) 治疗炎症或神经性疼痛的方法
TW202142229A (zh) 治療雷葛氏症候群之病患的方法
TWI428130B (zh) 治療急性躁狂症之藥學組成物及方法
TW202313003A (zh) 用於治療憂鬱之組成物及方法
US20240277698A1 (en) Methods of using aldosterone synthase inhibitors
US20240366582A1 (en) Treatment of raynaud&#39;s disease
US20240082225A1 (en) Methods for the treatment of dyskinesia in cerebral palsy
JP2009515952A (ja) 制御放出性製剤のクエチアピン
AU2023226657A1 (en) Compositions and methods for treatment of depression and other disorders
Ciccone Geriatric pharmacology
Gentile Pregnancy exposure to serotonin reuptake inhibitors and the risk of spontaneous abortions
JP2024540104A (ja) アルツハイマー病に関連する激越を治療する方法
US20250295648A1 (en) Method for treating l-dopa-induced dyskinesia, parkinson&#39;s disease, or parkinson&#39;s disease motor disability using befiradol
Tablets et al. PrZOLMITRIPTAN ODT
AU2024238367A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
WO2026085331A1 (en) Mefluleucin for use in the treatment of suicidal ideations associated with depression
Bajorek et al. Adverse reactions to medication
HK40061449A (en) Methods of treating inflammation or neuropathic pain
EFFEXOR HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EFFEXOR XR safely and effectively. See full prescribing information for
TW202521100A (zh) 使用ｇｌｐ－１受體促效劑及第二活性劑之組合治療睡眠呼吸中止之方法及組合物
Fuller Clinical psychopharmacology
Works et al. properties at sigma 1 receptors

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted